Login to Your Account



Financings Roundup

Exelixis Looking to Complete Public and Debt Financings

By Peter Winter
BioWorld Insight Editor

Tuesday, August 7, 2012
To help fuel its clinical trials programs on lead product candidate, cabozantinib, Exelixis Inc. (NASDAQ:EXEL) said it is planning an underwritten debt offering of $225 million convertible senior subordinated notes due 2019 and a concurrent sale of 20 million shares of its common stock.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription